Radiotherapy in brain metastases from EGFR-mutated non-small cell lung cancer

Epidermal growth factor receptor (EGFR) mutations are present in 20–40% of non-small cell lung cancers (NSCLCs). Brain metastasis (BM) is more common in EGFR-mutated NSCLC (25–45%) compared to EGFR wild-type (15–30%). First and second-generation tyrosine kinase inhibitors (TKIs), such as erlotinib a...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhandari, Shruti, Dunlap, Neal, Kloecker, Goetz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Review Article on Radiotherapy for Brain Metastases from Lung Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8182502/
https://www.ncbi.nlm.nih.gov/pubmed/34164215
http://dx.doi.org/10.21037/jtd-2019-rbmlc-04

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8182502/
https://www.ncbi.nlm.nih.gov/pubmed/34164215
http://dx.doi.org/10.21037/jtd-2019-rbmlc-04

Ejemplares similares